Twist Bioscience Corp
twistbioscience.comTwist Bioscience Corp (NASDAQ: TWST) is a synthetic biology company that manufactures synthetic DNA and related products using a proprietary silicon chip-based DNA writing platform. Revenue comes from transactional sales of synthetic biology tools, next-generation sequencing (NGS) tools, and fee-for-service biopharma discovery partnerships. The company is headquartered in South San Francisco, California, with manufacturing operations also in Wilsonville, Oregon. Founded and led by CEO Emily M. Leproust, Twist reported $376.6 million in revenue for the fiscal year ended September 30, 2025, a 20% increase from $313.0 million in FY2024. Gross margin expanded to 50.7% from 42.6% over the same period. The Americas accounted for 60% of FY2025 revenue, EMEA 33%, and APAC 7%. Twist sold its DNA data storage business to Atlas Data Storage, Inc. in exchange for a minority equity stake, an upfront cash payment, a secured promissory note, and future royalties on Atlas product sales.
Products & Services
Products include synthetic genes, gene fragments, oligo pools (up to one million oligos, up to 500 nucleotides in length), cloned oligo pools, NGS tools, DNA libraries, synthetic RNA, IgG antibody proteins, and antibody discovery libraries. Services include end-to-end biopharma discovery services covering in vivo, in vitro, and in silico antibody discovery, library generation, developability assays, and antibody expression and characterization.
Revenue Model
Twist generates revenue through three streams: transactional product sales of synthetic genes and oligo pools (synthetic biology tools), transactional sales of NGS tools and DNA libraries, and fee-for-service biopharma discovery partnerships covering library generation, antibody screening, and characterization. Revenue for FY2025 was $376.6 million. The company also retains a royalty-based revenue share from Atlas Data Storage on future Atlas product sales.
Customers & Markets
Customers include pharmaceutical and biotechnology companies pursuing drug discovery and development, academic and commercial researchers conducting genomics and gene editing work, and companies building AI-enabled antibody discovery platforms. End markets include synthetic biology research, next-generation sequencing, CRISPR gene editing, mutagenesis, DNA origami, high-throughput reporter assays, and biologic drug discovery. The filing does not disclose individual customer names or customer concentration percentages.
Geographic Exposure
Americas: $225.6 million, 60% of FY2025 revenue. EMEA: $124.2 million, 33%. APAC: $26.8 million, 7%. All figures for the fiscal year ended September 30, 2025.
Financial Snapshot
Loading...
